Skip to content

PP&E (Net) at other companies

Pfizer logo
PfizerPFE
$19.4B+5.8%
CG Oncology logo
CG OncologyCGON
$15.07M+5,610%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$3.2M-42.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.4M-6.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$38M-17.4%
Erasca, Inc. logo
Erasca, Inc.ERAS
$12.61M-19.1%

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.0%
Enterprise value$923.07M+23.5%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0.0×
Current ratio16.3×+4.3×

Where this comes from

Reported directly by Oric Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s PP&E (net)?
Oric Pharmaceuticals, Inc. (ORIC) reported PP&E (net) of $2.15M in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s PP&E (net) changed year-over-year?
Oric Pharmaceuticals, Inc.'s PP&E (net) decreased by 28.9% year-over-year, from $3.02M to $2.15M.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s PP&E (net) has grown at a 4.0% compound annual growth rate (CAGR), from $1.98M to $2.42M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.